Literature DB >> 26092814

Immunology of a Transmissible Cancer Spreading among Tasmanian Devils.

Gregory M Woods1, Lauren J Howson2, Gabriella K Brown2, Cesar Tovar2, Alexandre Kreiss2, Lynn M Corcoran3, A Bruce Lyons4.   

Abstract

Devil facial tumor disease (DFTD) is a transmissible cancer that has killed most of the Tasmanian devil (Sarcophilus harrissii) population. Since the first case appeared in the mid-1990s, it has spread relentlessly across the Tasmanian devil's geographic range. As Tasmanian devils only exist in Tasmania, Australia, DFTD has the potential to cause extinction of this species. The origin of DFTD was a Schwann cell from a female devil. The disease is transmitted when devils bite each other around the facial areas, a behavior synonymous with this species. Every devil that is 'infected' with DFTD dies from the cancer. Once the DFTD cells have been transmitted, they appear to develop into a cancer without inducing an immune response. The DFTD cancer cells avoid allogeneic recognition because they do not express MHC class I molecules on the cell surface. A reduced genetic diversity and the production of immunosuppressive cytokines may also contribute.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26092814     DOI: 10.4049/jimmunol.1500131

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Mitogen-activated Tasmanian devil blood mononuclear cells kill devil facial tumour disease cells.

Authors:  Gabriella K Brown; Cesar Tovar; Anne A Cooray; Alexandre Kreiss; Jocelyn Darby; James M Murphy; Lynn M Corcoran; Silvana S Bettiol; A Bruce Lyons; Gregory M Woods
Journal:  Immunol Cell Biol       Date:  2016-04-19       Impact factor: 5.126

2.  Two Decades of the Impact of Tasmanian Devil Facial Tumor Disease.

Authors:  Gregory M Woods; Samantha Fox; Andrew S Flies; Cesar D Tovar; Menna Jones; Rodrigo Hamede; David Pemberton; A Bruce Lyons; Silvana S Bettiol
Journal:  Integr Comp Biol       Date:  2018-12-01       Impact factor: 3.326

3.  Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils.

Authors:  Ruth Pye; Rodrigo Hamede; Hannah V Siddle; Alison Caldwell; Graeme W Knowles; Kate Swift; Alexandre Kreiss; Menna E Jones; A Bruce Lyons; Gregory M Woods
Journal:  Biol Lett       Date:  2016-10       Impact factor: 3.703

4.  PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment.

Authors:  Andrew S Flies; A Bruce Lyons; Lynn M Corcoran; Anthony T Papenfuss; James M Murphy; Graeme W Knowles; Gregory M Woods; John D Hayball
Journal:  Front Immunol       Date:  2016-12-09       Impact factor: 7.561

5.  ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1).

Authors:  Dane A Hayes; Dale A Kunde; Robyn L Taylor; Stephen B Pyecroft; Sukhwinder Singh Sohal; Elizabeth T Snow
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

6.  Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild Release.

Authors:  Ruth Pye; Amanda Patchett; Elspeth McLennan; Russell Thomson; Scott Carver; Samantha Fox; David Pemberton; Alexandre Kreiss; Adriana Baz Morelli; Anabel Silva; Martin J Pearse; Lynn M Corcoran; Katherine Belov; Carolyn J Hogg; Gregory M Woods; A Bruce Lyons
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

Review 7.  Metastasis in the wild: investigating metastasis in non-laboratory animals.

Authors:  Bushra Abu-Helil; Louise van der Weyden
Journal:  Clin Exp Metastasis       Date:  2019-02-09       Impact factor: 5.150

Review 8.  The urgent need to recover MHC class I in cancers for effective immunotherapy.

Authors:  Federico Garrido; Natalia Aptsiauri; Elien M Doorduijn; Angel M Garcia Lora; Thorbald van Hall
Journal:  Curr Opin Immunol       Date:  2016-01-18       Impact factor: 7.486

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.